Search for dissertations about: "ibrutinib"

Showing result 1 - 5 of 10 swedish dissertations containing the word ibrutinib.

  1. 1. Mantle cell lymphoma strategies in primary treatment

    Author : Alexandra Albertsson Lindblad; Tumörmikromiljö; []
    Keywords : MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; mantle cell lymphoma; registry data; Clinical Trial; Phase I; Clinical Trial; Phase II; rituximab; bendamustine; lenalidomid; ibrutinib; ADCC; in vitro model; TP53 mutations; watchful waiting; mantle cell lymphoma; real-world data; lenalidomide; rituximab; bendamustin; ibrutinib; ADCC; TP53 mutation; CDKN2A; NGS; MIPI; Watchful waiting;

    Abstract : Mantle cell lymphoma (MCL) is associated with poor prognosis due to an aggressive clinical course. Being a rare disease, there are few randomized trials in MCL and there is no defined golden standard in primary treatment. READ MORE

  2. 2. Targeted therapy in chronic lymphocytic leukemia

    Author : Maria Winqvist; Karolinska Institutet; Karolinska Institutet; []
    Keywords : MEDICAL AND HEALTH SCIENCES; MEDICIN OCH HÄLSOVETENSKAP;

    Abstract : Chronic lymphocytic leukemia (CLL) is characterized by the accumulation of mature B lymphocytes in blood, bone marrow and lymphoid tissues. Historically, patients with TP53 aberration and with refractoriness to chemoimmunotherapy had a dismal prognosis. READ MORE

  3. 3. Bruton tyrosine kinase in immunodeficiency and in B-cell malignancy

    Author : Qing Wang; Karolinska Institutet; Karolinska Institutet; []
    Keywords : MEDICAL AND HEALTH SCIENCES; MEDICIN OCH HÄLSOVETENSKAP;

    Abstract : BTK inhibitors have induced high response rates in the treatment of leukemias and lymphomas. Ibrutinib is the first-in-class US Food and Drug Administration (FDA)-approved BTK covalent inhibitor to treat chronic lymphocytic leukemia (CLL). However, a sub-group of patients develops resistance to ibrutinib therapy. READ MORE

  4. 4. The role of estrogens and the microenvironment in lymphoma progression and drug sensitivity

    Author : Jiyu Guan; Karolinska Institutet; Karolinska Institutet; []
    Keywords : MEDICAL AND HEALTH SCIENCES; MEDICIN OCH HÄLSOVETENSKAP;

    Abstract : Lymphomas are a group of cancers which originate from lymphatic cells. More than 90% of the lymphomas belong to the group of Non-Hodgkin lymphoma (NHL), which in itself is a non-homogeneous group consisting of different NHL subtypes. Traditionally, lymphomas are not thought of as hormone-related cancers. READ MORE

  5. 5. Effects of mutations in lymphoid malignancy and immunodeficiency disease

    Author : Abdulrahman M. Hamasy; Karolinska Institutet; Karolinska Institutet; []
    Keywords : MEDICAL AND HEALTH SCIENCES; MEDICIN OCH HÄLSOVETENSKAP;

    Abstract : Mutations are responsible for causing various human diseases, including several types of cancer and immunodeficiency syndromes. They can either be involved directly in the pathogenesis of the disease or by influencing the treatment efficacy and cause failure of the patient’s response to a specific therapy by adapting the targeted cell to resist the treatment. READ MORE